Mydecine Innovations Group, Inc., is pleased to announce that its wholly-owned subsidiary, Mindleap Health, has implemented a comprehensive information security rollout of next-generation cyber-security solutions to meet HIPAA compliance standards.
DENVER, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), is pleased to announce that its wholly-owned subsidiary, Mindleap Health (“Mindleap”), has implemented a comprehensive information security rollout of next-generation cyber-security solutions to meet HIPAA compliance standards. Mindleap also welcomes its new Director of Program Management, Dyson Walker, who will support Mindleap in improving its platform and meeting and exceeding all relevant laws and regulations.
HIPAA Compliance Certification
The Health Insurance Portability and Accountability Act, also known as HIPAA, is US legislation that provides security provisions to safeguard medical information. The Mindleap software development and security team have undergone a comprehensive multi-step verification process to ensure full HIPAA compliance and adherence with the following regulations:
Mindleap Chief Technology Officer, Simon Abou-Antoun, commented, “Mindleap recognizes the immense responsibility that comes with collecting, storing, and managing personal data about users’ mental health. Given the highly sensitive nature of this data, we owe it to ourselves, our users, and our partners to establish secure processes and systems that protect users. Our system offers secure communication, is compliant with HIPAA and we are pleased to have implemented next generation cybersecurity platforms to ensure maximum protection of our users’ data.”
Next-Gen Cyber Security Implementation
Mindleap has put together a comprehensive and fully operational security strategy and rollout to ensure administrative, physical, and technical safeguards are in place in order to protect the confidentiality, integrity, and availability of its sensitive data, including, without limitation, protected health information.
The next-generation security solutions include virus and exploit protection, encryption, network security, email security as well as a system for secure communication that protects the integrity of ePHI. (Electronic Personal Health Information) and a system of monitoring communications containing ePHI to prevent accidental or malicious breaches. Mindleap’s policies for securing data are following established and modern healthcare protocols all while being able to provide a secure and seamless service to clients.
Chief Compliance Officer, Dyson Walker
Mr. Walker is a proven IT professional with a wide range of experience managing large, complex projects in Europe, Asia and North America. Dyson has spent over 15 years in the Canadian Health System, 10 of which entailed working the British Columbia Ministry of Health, Provincial Telehealth Office (PTO) whose mandate was to support the expansion of telehealth in the Province. During Dyson’s tenure at the Ministry, some of his major achievements were:
- Successfully represented the Government of British Columbia on two federal pan- Canadian telehealth initiatives with participation by 12 of the 13 Canadian jurisdictions. Each initiative resulted in signed national agreements wtih major vendors and significantly accelerated the expansion of telehealth in Canada.
- Worked extensively with BC First Nations and local health authorities to support improved health care access via telehealth to their rural, underserved communities. Dyson was engaged with First Nations executive leadership at the federal, provincial and community levels. These First Nations led initiatives resulted in improved health outcomes.
- Acted as Program Manager for the $52M Home Health Monitoring Enabling Services (HHMES) initiative, a public, private partnership (PPP) between the BC Government and TELUS. HHMES comprised of six provincial technology projects that would accelerate adoption and expansion of telehealth in the Province. As Program Manager, Mr. Walker was responsible for four of the six projects with an estimated value of $20M.
Mindleap founder and CEO, Nikolai Vassev, commented: “We have taken every step and precaution in guaranteeing privacy and confidentiality on our platform and are incredibly pleased with the progress our security and compliance team have made in such a short time. We are also thrilled to have an experienced executive like Dyson Walker and lead our efforts in improving our platform.”
About Mydecine Innovations Group, Inc.
Mydecine Innovations Group™ is a publicly traded life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.
About Mindleap Health Inc.
Mindleap is developing an advanced digital health platform that will provide support for people that are looking to achieve personal transformations and overcome mental health challenges. Mindleap is the only digital health platform that combines telehealth with mood, emotion and habit tracking. This is a paradigm shift to conventional mental health as Mindleap personalized support and users have the tools needed to track their progress and take control of their mental health.
Learn about The Past and Future of Psychedelics as a Medicine
Apply to become a Specialist on Mindleap
For further information about Mydecine Innovations Group Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.
On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
contact@mydecineinc.com
Corp Communication:
Charles Lee, Investor Relations
corp@mydecineinc.com
+1 (250) 488-6728
Public Relations:
Cynthia Salarizadeh, PR
pr@mydecineinc.com
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward- looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.
